Code
MOG-EHDX-04CX
Test
Active-Compendium
Clinical
Pathology
Clinical Significance
This specimen hold option is useful for reserving specimens for molecular testing at a future date.
Flag Active
True
Orderable Test Description
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 11pt; font-family: 'aptos narrow' , sans-serif; color: black;"><span style="font-size: 11pt; line-height: 115%; font-family: 'aptos narrow' , sans-serif; color: black;">DNA, RNA or TNA (total nucleic acid: DNA and RNA together) will be isolated from viable cells and frozen. Analysis is not performed until clients order Molecular Testing. Processed samples are retained for 28 days.<br>Charges will be waived when testing is ordered on held specimens or a fee will be billed to client if no testing is ordered. For more information, please contact Client Services at 866.776.5907, option 3.<br>This specimen hold service is best used when it is known which test(s) may be ordered on the specimen. If possible, please make note of potential tests when ordering this service.<br>Below are specific tests for each extraction type.</span></span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 11pt; font-family: 'aptos narrow' , sans-serif; color: black;"><span style="font-size: 11pt; line-height: 115%; font-family: 'aptos narrow' , sans-serif; color: black;">Extract & Hold DNA: B-Cell Gene Rearrangement, BRAF Mutation Analysis by PCR, BTK Inhibitor Acquired Resistance Panel, CEBPA Mutation Analysis, CSF3R Mutation Analysis, CXCR4 Mutation Analysis, FLT3 Mutation Analysis, IDH1/IDH2 Mutation Analysis by PCR, IgH Clonality by NGSJAK2 V617F Mutation Analysis – Quantitative, KIT (c-KIT) Mutation Analysis, MPL Mutation AnalysisMYD88 Mutation Analysis, NOTCH1 Mutation Analysis, NPM1 MRD Analysis, NPM1 Mutation Analysis, NRAS Mutation Analysis, Rapid AML Therapeutic Panel, T-Cell Receptor Beta Gene Rearrangement, T-Cell Receptor Gamma Gene Rearrangement, TP53 Mutation Analysis.</span></span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 11pt; font-family: 'aptos narrow' , sans-serif; color: black;"><span style="font-size: 11pt; line-height: 115%; font-family: 'aptos narrow' , sans-serif; color: black;">Extract & Hold RNA: ABL1 Kinase Domain Mutation Analysis, BCR-ABL1 Non-Standard p230, BCR-ABL1 Standard p210, p190, IgVH Mutation Analysis inv(16), CBFB-MYH11 Translocation, JAK2 Exon 12-13 Mutation Analysis, JAK2 V617F Mutation Analysis – Qualitative, PML-RARA Translocation, t(15;17), RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21).</span></span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 11pt; font-family: 'aptos narrow' , sans-serif; color: black;"><span style="font-size: 11pt; line-height: 115%; font-family: 'aptos narrow' , sans-serif; color: black;">Note: If considering the MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, and MPL assay as an add-on to either JAK2 V617F Mutation Analysis - Qualitative or JAK2 Exon 12-13 Mutation Analysis, we recommend adding Extract & Hold - DNA with Extract & Hold - RNA order.</span></span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 11pt; font-family: 'aptos narrow' , sans-serif; color: black;">Neo Comprehensive - Heme Cancers, Neo Comprehensive - Myeloid Disorders, NeoTYPE ALL Profile, NeoTYPE ALL Profile for New York, NeoTYPE Follicular Lymphoma Profile, NeoTYPE® AITL/Peripheral T-Cell Lymphoma Profile, NeoTYPE® AML Prognostic Profile, NeoTYPE® CLL Profile, NeoTYPE® Lymphoid Disorders Profile, NeoTYPE® Lymphoma Profile, NeoTYPE® MDS/CMML Profile<br>Note: Specimen stability for Neo Comprehensive - Heme Cancers and Neo Comprehensive - Myeloid Disorders is 7 days from collection. Extract & Hold TNA must have been completed within 7 days from collection for testing to be added-on.</span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 11pt; font-family: 'aptos narrow' , sans-serif; color: black;"><span style="font-size: 11pt; line-height: 115%; font-family: 'aptos narrow' , sans-serif; color: black;">Extract & Hold DNA: B-Cell Gene Rearrangement, BRAF Mutation Analysis by PCR, BTK Inhibitor Acquired Resistance Panel, CEBPA Mutation Analysis, CSF3R Mutation Analysis, CXCR4 Mutation Analysis, FLT3 Mutation Analysis, IDH1/IDH2 Mutation Analysis by PCR, IgH Clonality by NGSJAK2 V617F Mutation Analysis – Quantitative, KIT (c-KIT) Mutation Analysis, MPL Mutation AnalysisMYD88 Mutation Analysis, NOTCH1 Mutation Analysis, NPM1 MRD Analysis, NPM1 Mutation Analysis, NRAS Mutation Analysis, Rapid AML Therapeutic Panel, T-Cell Receptor Beta Gene Rearrangement, T-Cell Receptor Gamma Gene Rearrangement, TP53 Mutation Analysis.</span></span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 11pt; font-family: 'aptos narrow' , sans-serif; color: black;"><span style="font-size: 11pt; line-height: 115%; font-family: 'aptos narrow' , sans-serif; color: black;">Extract & Hold RNA: ABL1 Kinase Domain Mutation Analysis, BCR-ABL1 Non-Standard p230, BCR-ABL1 Standard p210, p190, IgVH Mutation Analysis inv(16), CBFB-MYH11 Translocation, JAK2 Exon 12-13 Mutation Analysis, JAK2 V617F Mutation Analysis – Qualitative, PML-RARA Translocation, t(15;17), RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21).</span></span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 11pt; font-family: 'aptos narrow' , sans-serif; color: black;"><span style="font-size: 11pt; line-height: 115%; font-family: 'aptos narrow' , sans-serif; color: black;">Note: If considering the MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, and MPL assay as an add-on to either JAK2 V617F Mutation Analysis - Qualitative or JAK2 Exon 12-13 Mutation Analysis, we recommend adding Extract & Hold - DNA with Extract & Hold - RNA order.</span></span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 11pt; font-family: 'aptos narrow' , sans-serif; color: black;">Neo Comprehensive - Heme Cancers, Neo Comprehensive - Myeloid Disorders, NeoTYPE ALL Profile, NeoTYPE ALL Profile for New York, NeoTYPE Follicular Lymphoma Profile, NeoTYPE® AITL/Peripheral T-Cell Lymphoma Profile, NeoTYPE® AML Prognostic Profile, NeoTYPE® CLL Profile, NeoTYPE® Lymphoid Disorders Profile, NeoTYPE® Lymphoma Profile, NeoTYPE® MDS/CMML Profile<br>Note: Specimen stability for Neo Comprehensive - Heme Cancers and Neo Comprehensive - Myeloid Disorders is 7 days from collection. Extract & Hold TNA must have been completed within 7 days from collection for testing to be added-on.</span></p>
Keywords
Extra Note
Extract & Hold: Bone marrow, peripheral blood.
NY Approved
False
Keywords string
Nucleic acid extraction Extract and Hold Service, Hematologic Disorders
Title URL
extract-and-hold-service-hematologic-disorders